A number-needed-to-treat analysis of the use of respiratory syncytial virus immune globulin to prevent hospitalization

Archives of Pediatrics and Adolescent Medicine

Volumn 152, Issue 4, 1998, Pages 358-366

  Robbins, James M ^a,b   Tilford, John M ^a   Jacobs, Richard F ^a   Wheeler, J Gary ^a,b   Gillaspy, Stephen R ^a   Schutze, Gordon E ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b ARKANSAS CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; PLACEBO;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; FEVER; GASTROINTESTINAL TOXICITY; HOSPITALIZATION; HUMAN; HYPERTENSION; INFANT; INTRAVENOUS DRUG ADMINISTRATION; LUNG DYSPLASIA; MAJOR CLINICAL STUDY; PREMATURITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFECTION; TACHYCARDIA;

EID: 0031948530     PISSN: 10724710     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpedi.152.4.358     Document Type: Article

References (27)

1. PREVENT Study Group. Reduction of RSV hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics. 1997;99:93-99.
2. American Academy of Pediatrics, Committee on Infectious Diseases and Committee on Fetus and Newborn. Respiratory syncytial virus immune globulin intravenous: indications for use. Pediatrics. 1997;99:645-650.
3. Groothuis JR, Simoes EAF, Levin MJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med. 1993;329:1524-1530.
4. Simoes EAF, Sondheimer HM, Meissner HC, et al. Respiratory syncytial virus immunoglobulin as prophylaxis against respiratory syncytial virus in children with congenital heart disease [abstract]. Pediatr Res. 1996;39:113A.
5. RespiGam product information [package insert]. Gaithersburg, Md: Medimmune, Inc; 1996.
6. Ellenberg SS, Epstein JS, Fratantoni JC, et al. A trial of RSV immune globulin in infants and young children: the FDA's view. N Engl J Med. 1994;331:203-204.
7. Groothuis JR, Hemming VG, Siber OR, et al. Authors' reply to: A trial of RSV immune globulin in infants and young children: the FDA's view. N Engl J Med. 1994;331:204-205.
8. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ. 1995;310:452-454.
9. Kendrach MO, Covington TR, McCarthy MW, et al. Calculating risks and number-needed-to-treat: a method of data interpretation. J Managed Care Pharm. 1997; 3:179-183.
10. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med. 1988;318:1728-1733.
11. Smith GD, Egger M. Who benefits from medical interventions? BMJ. 1992;308: 72-74.
12. Guyatt OH, Sackett DL, Sinclair JC, et al. Users' guides to medical literature, IX: a method of grading health care recommendations. JAMA. 1995;274: 1800-1804.
13. Pauly MV. Valuing health care benefits in money terms. In: Sloan FA, ed. Valuing Health Care: Costs, Benefits, and Effectiveness of Pharmaceutical and Other Medical Technologies. New York, NY: Cambridge University Press; 1996: 99-124.
14. Hay JW, Ernst RL, Meissner HC. Respiratory syncytial virus immune globulin: a cost-effectiveness analysis. Am J Managed Care. 1996;2:851-861.
15. Grier CE, Howe BJ. Economic impact of pneumonia due to respiratory syncytial virus (RSV) infection. In: Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; American Society for Microbiology; September 15-18, 1995; New Orleans, La. Abstract N9.
16. Baker CJ, Melish ME, Hall RT, et al. Intravenous immune globulin for the prevention of nosocomial infection in low-birth-weight neonates. N Engl J Med. 1992; 327:213-219.
17. Buckley RH, Schiff RJ. The use of intravenous immune globulin in immunodeficiency disease. N Engl J Med. 1991;325:110-117.
18. Kim HW, Arrobio JO, Brandt CD, et al. Epidemiology of respiratory syncytial virus infection in Washington, DC, I: importance of the virus in different respiratory tract disease syndromes and temporal distribution of infection. Am J Epidemiol. 1973;98:216-225.
19. Navas L, Wang E, de Carvalho V, et al. Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children: Pediatric Investigators Collaborative Network on Infections in Canada. J Pediatr. 1992;121:3348-3354.
20. Meert KL, Sarnaik AP, Gelmini MJ, et al. Aerosolized ribavirin in mechanically ventilated infants with respiratory syncytial virus lower respiratory tract disease. Crit Care Med. 1994;22:566-572.
21. Meissner HC, Welliver RC, Chartrand SA, et al. Prevention of respiratory syncytial virus infection in high risk infants: consensus opinion on the role of immunoprophylaxis with respiratory syncytial virus hyperimmune globulin. Pediatr Infect Dis J. 1996;15:1059-1068.
22. Simoes EAF, Groothuis JR, Tristram DA, et al. Respiratory syncytial virus-enriched globulin for the prevention of acute otitis media in high-risk children. J Pediatr. 1996;129:214-219.
23. Appel LJ, Steinberg EP, Powe NR, et al. Risk reduction from low osmolality contrast media: what do patients think it is worth? Med Care. 1990;28: 24-37.
24. Berwick DM, Weinstein MC. What do patients value? willingness to pay for ultrasound in normal pregnancy. Med Care. 1985;23:881-893.
25. Donaldson C, Shackley P, Abdalla M, et al. Willingness to pay for antenatal carrier screening for cystic fibrosis. Health Econ. 1995;4:439-452.
26. Center for Health Statistics. Arkansas County Trends in Maternal and Child Health, 1990-1994. Little Rock: Arkansas Dept of Health; 1995.
27. Cunningham CK, McMillan JA, Gross SJ. Rehospitalization for respiratory illness in infants of less than 32 weeks' gestation. Pediatrics. 1991;88:527-532.